{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:36:10Z","timestamp":1791578170024,"version":"4.3.4"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>PLAIN ENGLISH SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2009<\/jats:title>\n                    <jats:p>Endothelin-1 (ET-1) is a peptide that is involved in various chronic diseases including cardiovascular and kidney disease. ET-1 can bind to two receptors, endothelin A (ETA) and endothelin B (ETB), which are found in different organs and tissues. When ET-1 binds to the ETA receptor, it causes blood vessels to narrow, while binding of ET-1 to the ETB receptor causes blood vessels to widen. These receptors help regulate fluid and electrolyte balance in the kidneys, as well as the kidney's ability to filter various substances out of the body. Overactivation of ET-1 can occur in people with diabetes or obesity, which can damage the structure and function of the kidney.<\/jats:p>\n                    <jats:p>Studies in mice and humans with kidney disease have shown that blocking the ETA receptor improves kidney health. As a result, medicines that specifically block the ETA receptor, known as endothelin receptor antagonists (ERAs), are a promising option for treating these kidney diseases. The first ERA (sparsentan) is now available for use in patients with immunoglobulin A (IgA) nephropathy, a specific type of kidney disease. It should be noted that ERAs can cause side effects. Fluid retention, which can increase the risk of heart failure, is a side effect that is particularly observed in patients with type 2 diabetes and severe kidney disease. This side effect is less often observed in patients with IgA nephropathy or patients without diabetes.<\/jats:p>\n                    <jats:p>Treatment strategies to optimize safe and effective use of ETA blockers are being developed. Overall, these insights offer hope for better care of patients with kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ABSTRACT<\/jats:title>\n                    <jats:p>Endothelin-1 (ET-1) is a 21\u2013amino acid peptide involved in numerous cardiovascular and renal processes. ET-1 can bind to endothelin receptor A (ETA) and endothelin receptor B (ETB), which are found in various organs and tissues. In general, binding of ET-1 to the ETA receptor causes vasoconstriction, whereas activation of the ETB receptor leads to vasodilation. In the kidney, endothelin receptors regulate fluid and electrolyte balance, regional blood flow and glomerular filtration rate. In pathological conditions, ET-1 promotes kidney injury through adverse effects on the endothelial glycocalyx, podocytes and mesangial cells, and stimulating inflammation and fibrosis in the tubules. In experimental and clinical studies, inhibition of the ETA receptor has been shown beneficial in a variety of kidney diseases. These include diabetic kidney disease, immunoglobulin A nephropathy, focal segmental glomerulosclerosis and Alport syndrome. Accordingly, selective ETA endothelin receptor antagonists (ERA) may prove a viable therapeutic option in these diseases. However, clinical application is challenged by the occurrence of fluid retention which can lead to heart failure, in particular in patients with severe CKD. Concomitant use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) may mitigate these adverse effects through their diuretic actions. The development of highly selective ETA antagonists, such as atrasentan and zibotentan, and the opportunities of combining these with SGLT2i, holds promise to optimize efficacy and safety of ERAs in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfae214","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:22:35Z","timestamp":1738743755000},"page":"i37-i46","source":"Crossref","is-referenced-by-count":29,"title":["Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application"],"prefix":"10.1093","volume":"40","author":[{"given":"Erik","family":"Moedt","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen , The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S","family":"Wasehuus","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center \u00a0 Copenhagen, Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen , The","place":["Netherlands"]},{"name":"The George Institute for Global Health , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025020513210726400_bib1","first-page":"1","article-title":"Endothelin 1","volume-title":"xPharm: the Comprehensive Pharmacology Reference [Internet]","author":"Perrine","year":"2007"},{"key":"2025020513210726400_bib2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2025020513210726400_bib3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bcp.2012.03.020","article-title":"Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease","volume":"84","author":"Mazzuca","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2025020513210726400_bib4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/cphy.c100039","article-title":"Physiology of endothelin and the kidney","volume":"1","author":"Kohan","year":"2011","journal-title":"Compr Physiol"},{"key":"2025020513210726400_bib5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025020513210726400_bib7","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.2337\/db15-1413","article-title":"Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy","volume":"65","author":"Boels","year":"2016","journal-title":"Diabetes"},{"key":"2025020513210726400_bib8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/HYPERTENSIONAHA.109.133579","article-title":"Treatment of chronic proteinuric kidney disease","volume":"54","author":"Benigni","year":"2009","journal-title":"Hypertension"},{"key":"2025020513210726400_bib9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.kint.2019.05.007","article-title":"Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells","volume":"96","author":"Ebefors","year":"2019","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib10","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1172\/JCI71195","article-title":"Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis","volume":"124","author":"Daehn","year":"2014","journal-title":"J Clin Invest"},{"key":"2025020513210726400_bib11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1681\/ASN.2013040362","article-title":"\u03b2-Arrestin-1 drives endothelin-1\u2013mediated podocyte activation and sustains renal injury","volume":"25","author":"Buelli","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210726400_bib12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000045906","article-title":"Effects of endothelin receptor antagonists on the progression of diabetic nephropathy","volume":"87","author":"Hocher","year":"2001","journal-title":"Nephron"},{"key":"2025020513210726400_bib13","doi-asserted-by":"publisher","first-page":"F977","DOI":"10.1152\/ajprenal.00182.2018","article-title":"Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade","volume":"315","author":"Spires","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513210726400_bib14","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/ndt\/gfae021","article-title":"Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy","volume":"39","author":"Nagasawa","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513210726400_bib15","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1016\/j.ekir.2021.03.396","article-title":"Pos-378 selective ETA antagonist atrasentan, rapidly reduces albuminuria and downregulates intra-renal pro-inflammatory and pro-fibrotic transcriptional networks in the gddy mouse model of spontaneous IgA nephropathy","volume":"6","author":"King","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025020513210726400_bib16","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20223311S133a","article-title":"Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis (FSGS)","volume-title":"ASN [Internet]","author":"Gyarmati","year":"2022  4"},{"key":"2025020513210726400_bib17","doi-asserted-by":"publisher","first-page":"gfac067.054","DOI":"10.1093\/ndt\/gfac067.054","article-title":"MO255: sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis (FSGS)","volume":"37","author":"Bedard","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513210726400_bib18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.kint.2016.02.018","article-title":"Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease","volume":"90","author":"Dufek","year":"2016","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/path.6087","article-title":"Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice","volume":"260","author":"Cosgrove","year":"2023","journal-title":"J Pathol"},{"key":"2025020513210726400_bib20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0014-2999(99)00535-X","article-title":"Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats","volume":"381","author":"Shimizu","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"2025020513210726400_bib21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/ki.2013.477","article-title":"Disparate effects of single endothelin A and B receptor blocker therapy on the progression of renal injury in advanced renovascular disease","volume":"85","author":"Chade","year":"2014","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/jpet.111.178988","article-title":"Distinct actions of endothelin A-selective versus combined endothelin A\/B receptor antagonists in early diabetic kidney disease","volume":"338","author":"Saleh","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2025020513210726400_bib23","doi-asserted-by":"publisher","first-page":"43152","DOI":"10.1038\/srep43152","article-title":"Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney","volume":"7","author":"De Miguel","year":"2017","journal-title":"Sci Rep"},{"key":"2025020513210726400_bib24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1681\/ASN.2014040323","article-title":"Endothelin-A receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease","volume":"26","author":"Chade","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210726400_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1258\/rsmacta.44.1.111","article-title":"Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia","volume":"44","author":"Liss","year":"2003","journal-title":"Acta Radiol"},{"key":"2025020513210726400_bib26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.lfs.2012.02.002","article-title":"Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental diabetic model","volume":"91","author":"Abu-Saleh","year":"2012","journal-title":"Life Sci"},{"key":"2025020513210726400_bib27","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1681\/ASN.2016070711","article-title":"Long-term endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice","volume":"28","author":"Kasztan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210726400_bib28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ki.2013.157","article-title":"Progressive endothelin-1 gene activation initiates chronic\/end stage renal disease following experimental ischemic-reperfusion injury","volume":"84","author":"Zager","year":"2013","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib29","article-title":"Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in"},{"key":"2025020513210726400_bib30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejphar.2014.03.002","article-title":"Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats","volume":"730","author":"Helmy","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2025020513210726400_bib31","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/cvr\/cvz260","article-title":"Selective ETA vs. dual ETA\/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats","volume":"116","author":"Mirabito Colafella","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2025020513210726400_bib32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1046\/j.1523-1755.2001.0590041333.x","article-title":"Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function","volume":"59","author":"Forbes","year":"2001","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib33","doi-asserted-by":"publisher","first-page":"F1173","DOI":"10.1152\/ajprenal.00040.2019","article-title":"Sustained, delayed, and small increments in glomerular permeability to macromolecules during systemic ET-1 infusion mediated via the ETA receptor","volume":"316","author":"Dolinina","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513210726400_bib34"},{"key":"2025020513210726400_bib35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00005344-200010000-00003","article-title":"Treatment with a combined endothelin A\/B-receptor antagonist does not prevent chronic renal allograft rejection in rats","volume":"36","author":"Braun","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025020513210726400_bib36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000444719","article-title":"and podocyte protection in chronic hypoxia: effects of endothelin-a receptor antagonism","volume":"43","author":"Harvey","year":"2016","journal-title":"Am J Nephrol"},{"key":"2025020513210726400_bib37","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210726400_bib38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"2025020513210726400_bib39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210726400_bib40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol Rev"},{"key":"2025020513210726400_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fphys.2012.00103","article-title":"Antidiuretic effects of the endothelin receptor antagonist avosentan","volume":"3","author":"Baltatu","year":"2012","journal-title":"Front Physiol"},{"key":"2025020513210726400_bib42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2369-13-166","article-title":"Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion","volume":"13","author":"Stuart","year":"2012","journal-title":"BMC Nephrol"},{"key":"2025020513210726400_bib43","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1172\/JCI116013","article-title":"Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting duct","volume":"90","author":"Nadler","year":"1992","journal-title":"J Clin Invest"},{"key":"2025020513210726400_bib44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0022-3565(25)39463-2","article-title":"Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor","volume":"267","author":"Edwards","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"2025020513210726400_bib45","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/01.RES.0000104086.43830.6C","article-title":"Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries","volume":"93","author":"Jeyabalan","year":"2003","journal-title":"Circ Res"},{"key":"2025020513210726400_bib46","doi-asserted-by":"publisher","first-page":"gfae112","DOI":"10.1093\/ndt\/gfae112","article-title":"Volenrelaxin (LY3540378) increases renal plasma flow: a randomized phase 1 trial","author":"Tham","year":"2024  23","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513210726400_bib47","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210726400_bib48","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025020513210726400_bib49","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025020513210726400_bib50","volume-title":"ALIGN Phase 3 Primary Endpoint Analysis: Atrasentan Shows Significant Reduction in Proteinuria in Patients with IgA Nephropathy","author":"Heerspink","year":"2024"},{"key":"2025020513210726400_bib51","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"2025020513210726400_bib52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nep.14130","article-title":"Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?","volume":"28","author":"Chung","year":"2023","journal-title":"Nephrology"},{"key":"2025020513210726400_bib53","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/jcm4061171","article-title":"Endothelin blockade in diabetic kidney disease","volume":"4","author":"Anguiano","year":"2015","journal-title":"J Clin Med"},{"key":"2025020513210726400_bib54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"2025020513210726400_bib55","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/sj.bjc.6602676","article-title":"Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence","volume":"92","author":"Morris","year":"2005","journal-title":"Br J Cancer"},{"key":"2025020513210726400_bib56","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2215\/CJN.07040713","article-title":"Predictors of congestive heart failure after treatment with an endothelin receptor antagonist","volume":"9","author":"Hoekman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513210726400_bib57","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jchf.2022.03.004","article-title":"Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure","volume":"10","author":"Smeijer","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025020513210726400_bib58","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/dom.13245","article-title":"Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obesity Metab"},{"key":"2025020513210726400_bib59","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020513210726400_bib60","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"2025020513210726400_bib61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/CS20240249","article-title":"Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease","volume":"138","author":"Kohan","year":"2024","journal-title":"Clin Sci (Lond)"},{"key":"2025020513210726400_bib62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.103.055855","article-title":"Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension","volume":"309","author":"Kowala","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2025020513210726400_bib63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int"},{"key":"2025020513210726400_bib64","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet North Am Ed"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i37\/61766393\/gfae214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i37\/61766393\/gfae214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:23:42Z","timestamp":1738743822000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/Supplement_1\/i37\/8002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":64,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae214","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}